IMPROVE and IMPROVEDD scores for venous thromboembolism: Difference between revisions
Tarek Nafee (talk | contribs) |
Tarek Nafee (talk | contribs) No edit summary |
||
Line 95: | Line 95: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Current [[malignancy]]|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2 | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Current [[malignancy]]|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2 | ||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |D-dimer ≥ 2x Upper Limit of Normal (ULN)|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2 | |||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Immobilization for at least 7 days|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1 | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |Immobilization for at least 7 days|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1 | ||
Line 103: | Line 105: | ||
|} | |} | ||
===Interpretation of the | ===Interpretation of the IMPROVEDD Associative Score=== | ||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | {| style="cellpadding=0; cellspacing= 0; width: 600px;" | ||
|- | |- | ||
Line 112: | Line 114: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |0.6% | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |0.6% | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |0.8% | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |3|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1. | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |3|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1.2% | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |4|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |4|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |1.6% | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |5-10|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |5-10|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |2.2% | ||
|} | |} | ||
Revision as of 14:14, 13 October 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
The IMPROVE score for venous thromboembolism (VTE) assesses the risk of VTE among hospitalized medical patients. The IMPROVE predictive score for VTE includes 4 independent risk factors for VTE which are present at admission. The IMPROVE associative score for VTE includes 7 variables present either at admission or during hospitalization; however the timing of the presence of some of the factors compared to the onset of VTE was not available.[1]
IMPROVE Predictive Score for VTE
Calculation of the IMPROVE Predictive Score
Variable | Score[1] |
Prior episode of VTE | 3 |
Thrombophilia | 3 |
Malignancy | 1 |
Age more than 60 years | 1 |
Interpretation of the IMPROVE Predictive Score
Score | Predicted VTE risk through 3 months[1] |
0 | 0.5% |
1 | 1.0% |
2 | 1.7% |
3 | 3.1% |
4 | 5.4% |
5-8 | 11% |
IMPROVE Associative Score for VTE
IMPROVE associative risk score assesses the risk of VTE among hospitalized medical patients. While the IMPROVE predictive score includes 4 independent risk factors for VTE which are present at admission, IMPROVE associative score includes 7 variables present either at admission or during hospitalization; however the timing of the presence of some of the factors compared to the onset of VTE is not available.[1]
Calculation of the IMPROVE Associative Score
Variable | Score[1] |
Prior episode of VTE | 3 |
Thrombophilia | 2 |
Paralysis of the lower extremity during the hospitalization | 2 |
Current malignancy | 2 |
Immobilization for at least 7 days | 1 |
ICU or CCU admission | 1 |
Age more than 60 years | 1 |
Interpretation of the IMPROVE Associative Score
Score | Predicted VTE risk through 3 months[1] |
0 | 0.4% |
1 | 0.6% |
2 | 1.0% |
3 | 1.7% |
4 | 2.9% |
5-10 | 7.2% |
IMPROVE-DD score for VTE risk stratification
IMPROVEDD VTE risk score assesses the risk of VTE among hospitalized medical patients. While the IMPROVE predictive score includes 4 independent risk factors for VTE which are present at admission, IMPROVE associative score includes 7 variables present either at admission or during hospitalization; however the timing of the presence of some of the factors compared to the onset of VTE is not available.[1]
Calculation of the IMPROVE Associative Score
Variable | Score[1] |
Prior episode of VTE | 3 |
Thrombophilia | 2 |
Paralysis of the lower extremity during the hospitalization | 2 |
Current malignancy | 2 |
D-dimer ≥ 2x Upper Limit of Normal (ULN) | 2 |
Immobilization for at least 7 days | 1 |
ICU or CCU admission | 1 |
Age more than 60 years | 1 |
Interpretation of the IMPROVEDD Associative Score
Score | Predicted VTE risk through 3 months[1] |
0 | 0.4% |
1 | 0.6% |
2 | 0.8% |
3 | 1.2% |
4 | 1.6% |
5-10 | 2.2% |